[go: up one dir, main page]

BRPI0818913A2 - Fator viii recombinante tendo elevada estabilidade - Google Patents

Fator viii recombinante tendo elevada estabilidade

Info

Publication number
BRPI0818913A2
BRPI0818913A2 BRPI0818913A BRPI0818913A2 BR PI0818913 A2 BRPI0818913 A2 BR PI0818913A2 BR PI0818913 A BRPI0818913 A BR PI0818913A BR PI0818913 A2 BRPI0818913 A2 BR PI0818913A2
Authority
BR
Brazil
Prior art keywords
factor viii
high stability
recombinant factor
recombinant
viii
Prior art date
Application number
Other languages
English (en)
Inventor
Philip J Fay
Hironao Wakabayashi
Original Assignee
Univ Rochester
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ Rochester filed Critical Univ Rochester
Publication of BRPI0818913A2 publication Critical patent/BRPI0818913A2/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/36—Blood coagulation or fibrinolysis factors
    • A61K38/37—Factors VIII
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/745—Blood coagulation or fibrinolysis factors
    • C07K14/755—Factors VIII, e.g. factor VIII C (AHF), factor VIII Ag (VWF)

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Hematology (AREA)
  • Zoology (AREA)
  • Engineering & Computer Science (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Toxicology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Diabetes (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Biomedical Technology (AREA)
  • Biotechnology (AREA)
  • Virology (AREA)
  • Wood Science & Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Physics & Mathematics (AREA)
  • Developmental Biology & Embryology (AREA)
  • Plant Pathology (AREA)
  • Microbiology (AREA)
BRPI0818913 2007-11-01 2008-07-25 Fator viii recombinante tendo elevada estabilidade BRPI0818913A2 (pt)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US98451807P 2007-11-01 2007-11-01
US99130407P 2007-11-30 2007-11-30
PCT/US2008/071170 WO2009058446A1 (en) 2007-11-01 2008-07-25 Recombinant factor viii having increased stability

Publications (1)

Publication Number Publication Date
BRPI0818913A2 true BRPI0818913A2 (pt) 2015-05-12

Family

ID=40588749

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI0818913 BRPI0818913A2 (pt) 2007-11-01 2008-07-25 Fator viii recombinante tendo elevada estabilidade

Country Status (13)

Country Link
US (4) US8338571B2 (pt)
EP (2) EP2209908B1 (pt)
JP (2) JP2011502478A (pt)
KR (1) KR20100113478A (pt)
CN (2) CN101965409A (pt)
AU (1) AU2008319183B2 (pt)
BR (1) BRPI0818913A2 (pt)
CA (1) CA2703948A1 (pt)
IL (1) IL205422A0 (pt)
MX (1) MX2010004813A (pt)
RU (2) RU2531493C2 (pt)
WO (1) WO2009058446A1 (pt)
ZA (1) ZA201003049B (pt)

Families Citing this family (40)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20090203077A1 (en) * 2006-06-30 2009-08-13 The Regents Of The University Of Michigan Method of producing factor viii proteins by recombinant methods
US20120028900A1 (en) * 2006-06-30 2012-02-02 Kaufman Randal J Method of producing factor viii proteins by recombinant methods
US20080070251A1 (en) * 2006-06-30 2008-03-20 Kaufman Randal J Method of Producing Factor VIII Proteins by Recombinant Methods
US9062299B2 (en) 2009-08-24 2015-06-23 Amunix Operating Inc. Coagulation factor IX compositions and methods of making and using same
ES2541369T3 (es) 2010-02-16 2015-07-17 Novo Nordisk A/S Factor VIII recombinante modificado
CA2807552A1 (en) 2010-08-06 2012-02-09 Moderna Therapeutics, Inc. Engineered nucleic acids and methods of use thereof
US8637448B2 (en) 2010-09-14 2014-01-28 University Of Rochester Recombinant factor VIII having enhanced stability following mutation at the A1-C2 domain interface
DE19177059T1 (de) 2010-10-01 2021-10-07 Modernatx, Inc. N1-methyl-pseudouracile enthältendes ribonucleinsäuren sowie ihre verwendungen
DE102010042458A1 (de) * 2010-10-14 2012-04-19 Siemens Aktiengesellschaft Verfahren zum Betreiben einer kombinierten Gas- und Dampfturbinenanlage sowie zur Durchführung des Verfahrens hergerichtete Gas- und Dampfturbinenanlage und entsprechende Regelvorrichtung
JP2014511687A (ja) 2011-03-31 2014-05-19 モデルナ セラピューティクス インコーポレイテッド 工学操作された核酸の送達および製剤
US9464124B2 (en) 2011-09-12 2016-10-11 Moderna Therapeutics, Inc. Engineered nucleic acids and methods of use thereof
HUE057725T2 (hu) 2011-10-03 2022-06-28 Modernatx Inc Módosított nukleozidok, nukleotidok és nukleinsavak és ezek felhasználása
HRP20220717T1 (hr) 2011-12-16 2022-07-22 Modernatx, Inc. Modificirani pripravci mrna
CN109111526A (zh) * 2012-01-12 2019-01-01 比奥贝拉蒂治疗公司 嵌合因子viii多肽及其用途
BR112014019901A8 (pt) 2012-02-15 2018-01-02 Biogen Idec Inc Proteínas de fator viii recombinante
EP3564260B1 (en) 2012-02-15 2022-10-19 Bioverativ Therapeutics Inc. Factor viii compositions and methods of making and using same
JP2015516143A (ja) 2012-04-02 2015-06-08 モデルナ セラピューティクス インコーポレイテッドＭｏｄｅｒｎａ Ｔｈｅｒａｐｅｕｔｉｃｓ，Ｉｎｃ． ヒト疾患に関連するタンパク質の産生のための修飾ポリヌクレオチド
US9303079B2 (en) 2012-04-02 2016-04-05 Moderna Therapeutics, Inc. Modified polynucleotides for the production of cytoplasmic and cytoskeletal proteins
US9572897B2 (en) 2012-04-02 2017-02-21 Modernatx, Inc. Modified polynucleotides for the production of cytoplasmic and cytoskeletal proteins
US9283287B2 (en) 2012-04-02 2016-03-15 Moderna Therapeutics, Inc. Modified polynucleotides for the production of nuclear proteins
EP2666782A1 (en) * 2012-05-22 2013-11-27 Imnate Sarl Coagulation factor VIII with reduced immunogenicity.
HUE047088T2 (hu) 2012-07-11 2020-04-28 Bioverativ Therapeutics Inc VIII. faktor komplex XTEN-nel és von willebrand-faktor fehérjével, és alkalmazásai
SMT202200337T1 (it) 2012-11-26 2022-09-14 Modernatx Inc Rna modificato al livello del terminale
EP2988758B1 (en) 2013-03-15 2018-04-25 Bayer HealthCare LLC Variant factor viii polypeptides and methods of their production and use
US8980864B2 (en) 2013-03-15 2015-03-17 Moderna Therapeutics, Inc. Compositions and methods of altering cholesterol levels
TWI667255B (zh) 2013-08-14 2019-08-01 美商生物化學醫療公司 因子ｖｉｉｉ－ｘｔｅｎ融合物及其用途
EP4108254A1 (en) * 2013-08-14 2022-12-28 Bioverativ Therapeutics Inc. Recombinant factor viii proteins
WO2015051214A1 (en) 2013-10-03 2015-04-09 Moderna Therapeutics, Inc. Polynucleotides encoding low density lipoprotein receptor
AU2014339034A1 (en) * 2013-10-22 2016-05-19 Dbv Technologies Method of treating haemophilia by inducing tolerance to blood factors
CN103613658B (zh) * 2013-11-15 2015-04-01 同路生物制药股份有限公司 一种人第viii凝血因子的制备方法
GB201322091D0 (en) 2013-12-13 2014-01-29 Cambridge Entpr Ltd Modified serpins for the treatment of bleeding disorders
HUE059820T2 (hu) 2014-01-10 2022-12-28 Bioverativ Therapeutics Inc VIII-as faktor kimérafehérjéi és azok alkalmazása
EP3114138B1 (en) 2014-03-05 2021-11-17 Pfizer Inc. Improved muteins of clotting factor viii
WO2017011275A1 (en) 2015-07-10 2017-01-19 Nersissian Aram M Factor viii protein compositions and methods of treating hemophilia a
IL257231B (en) 2015-08-03 2022-09-01 Bioverativ Therapeutics Inc Factor ix fusion proteins and methods of making and using same
EP3352787A1 (en) 2015-09-24 2018-08-01 BioMarin Pharmaceutical Inc. Adeno-associated virus factor viii vectors, associated viral particles and therapeutic formulations comprising the same
EP3548066A1 (en) 2016-12-02 2019-10-09 Bioverativ Therapeutics Inc. Methods of treating hemophilic arthropathy using chimeric clotting factors
HRP20250709T1 (hr) 2018-05-18 2025-08-15 Bioverativ Therapeutics Inc. Postupci liječenja hemofilije a
EP3829650A4 (en) 2018-08-03 2022-05-04 Sangamo Therapeutics, Inc. IMPROVED CLINICAL PARAMETERS BY EXPRESSION OF FACTOR VIII
JP7672334B2 (ja) 2018-10-23 2025-05-07 ザ・チルドレンズ・ホスピタル・オブ・フィラデルフィア 第ｖｉｉｉ因子機能を調節するための組成物および方法

Family Cites Families (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4237224A (en) 1974-11-04 1980-12-02 Board Of Trustees Of The Leland Stanford Jr. University Process for producing biologically functional molecular chimeras
US5451521A (en) * 1986-05-29 1995-09-19 Genetics Institute, Inc. Procoagulant proteins
US5859204A (en) 1992-04-07 1999-01-12 Emory University Modified factor VIII
US6376463B1 (en) * 1992-04-07 2002-04-23 Emory University Modified factor VIII
US5576291A (en) 1993-09-13 1996-11-19 Baxter International Inc. Activated factor VIII as a therapeutic agent and method of treating factor VIII deficiency
US5880327A (en) * 1994-09-21 1999-03-09 American National Red Cross Transgenic mammals expressing human coagulation factor VIII
US20040092442A1 (en) 1996-04-24 2004-05-13 University Of Michigan Inactivation resistant factor VIII
US8183344B2 (en) 1996-04-24 2012-05-22 University Of Michigan Inactivation resistant factor VIII
US6458563B1 (en) * 1996-06-26 2002-10-01 Emory University Modified factor VIII
US6593291B1 (en) * 1997-02-06 2003-07-15 Entremed, Inc. Compositions and methods of use of ligands that bind components of the blood coagulation/clotting pathway for the treatment of cancer and angiogenic-based disease
US5804420A (en) * 1997-04-18 1998-09-08 Bayer Corporation Preparation of recombinant Factor VIII in a protein free medium
US5994310A (en) 1998-09-03 1999-11-30 Bayer Corporation Peptide ligands for affinity purification of human Factor VIII
US6759216B1 (en) 1998-11-06 2004-07-06 Emory University Glycosylated, low antigenicity low immunogenicity factor VIII
EP1038959A1 (en) 1999-03-17 2000-09-27 Aventis Behring Gesellschaft mit beschränkter Haftung Factor VIII without B-domain, comprising one or more insertions of a truncated intron I of factor IX
NZ516400A (en) 1999-07-13 2004-02-27 Biovitrum Ab Stable factor VIII compositions
US7771929B2 (en) * 2000-04-28 2010-08-10 Monogram Biosciences, Inc. Tag library compounds, compositions, kits and methods of use
WO2002024723A1 (en) * 2000-09-19 2002-03-28 Emory University Modified factor viii
EP1233064A1 (en) 2001-02-09 2002-08-21 Aventis Behring Gesellschaft mit beschränkter Haftung Modified factor VIII cDNA and its use for the production of factor VIII
US7205278B2 (en) 2001-06-14 2007-04-17 The Scripps Research Institute Stabilized proteins with engineered disulfide bonds
EP1424344A1 (en) 2002-11-29 2004-06-02 Aventis Behring Gesellschaft mit beschränkter Haftung Modified cDNA factor VIII and its derivates
US7041635B2 (en) * 2003-01-28 2006-05-09 In2Gen Co., Ltd. Factor VIII polypeptide
AU2004296768B2 (en) 2003-12-03 2010-06-24 University Of Rochester Recombinant factor VIII having increased specific activity
ATE401054T1 (de) * 2004-06-04 2008-08-15 Camurus Ab Flüssige depotformulierungen

Also Published As

Publication number Publication date
CN104152489A (zh) 2014-11-19
EP2711436A1 (en) 2014-03-26
CA2703948A1 (en) 2009-05-07
US20090118184A1 (en) 2009-05-07
RU2010122052A (ru) 2011-12-10
AU2008319183B2 (en) 2014-09-04
US20090118185A1 (en) 2009-05-07
WO2009058446A1 (en) 2009-05-07
RU2531493C2 (ru) 2014-10-20
AU2008319183A1 (en) 2009-05-07
US9072722B2 (en) 2015-07-07
EP2209908A1 (en) 2010-07-28
JP2015110589A (ja) 2015-06-18
US20140056861A1 (en) 2014-02-27
EP2209908A4 (en) 2011-06-01
ZA201003049B (en) 2012-11-28
CN101965409A (zh) 2011-02-02
US8183345B2 (en) 2012-05-22
MX2010004813A (es) 2010-10-04
EP2209908B1 (en) 2014-09-03
JP2011502478A (ja) 2011-01-27
KR20100113478A (ko) 2010-10-21
RU2014129759A (ru) 2016-02-10
US8338571B2 (en) 2012-12-25
IL205422A0 (en) 2010-12-30
US20130085110A1 (en) 2013-04-04

Similar Documents

Publication Publication Date Title
BRPI0818913A2 (pt) Fator viii recombinante tendo elevada estabilidade
PL2465864T3 (pl) Szczepionki z peptydem pochodzącym z Eph4
EP2215246A4 (en) PROTEIN SCAFFOLDS
NO20084339L (no) Stabiliserte polypeptidsammensetninger
DK3425646T3 (da) Højspændingstransformer
BRPI0911743A2 (pt) "peptídeo"
DK3118221T3 (da) Proteiner
DE102007063274B8 (de) Mikroskop
DK2035447T3 (da) Polypeptid
EP2131749A4 (en) Surgical stapling apparatus
DK2171053T3 (da) Natriuretiske polypeptider
EP2075615A4 (en) MICROSCOPE
BRPI0821668A2 (pt) Uso
BRPI0813647A2 (pt) Piperazinil oxoalquil tetrahidro-beta-carbolinas e análogos relacionados
BRPI0911849A2 (pt) protetores solares
DE602007001859D1 (de) Teleskopischer Stellantrieb
EP2245315A4 (en) O-HEAD DESIGN
DE602007004931D1 (de) Teleskopischer Stellantrieb
BRPI0818738A2 (pt) atuador linear telescópico
DE502007003199D1 (de) Schutzbalg
DE502007005032D1 (de) Der Astromischer
DE102008014880A8 (de) Antientzündliches Polypeptid
EP2439209A4 (en) ENDOKININ-C / D-PEPTIDE
DE502007003234D1 (de) Balgeinrichtung
DK2081952T3 (da) Peptider

Legal Events

Date Code Title Description
B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]
B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]